Gilead's Kite Forms AML Collaboration With HiFiBiO Therapeutics
September 03 2020 - 8:56AM
Dow Jones News
By Colin Kellaher
Gilead Sciences Inc. on Thursday said its Kite unit signed a
two-year research collaboration and license agreement with
biotherapeutics startup HiFiBiO Therapeutics targeting acute
myeloid leukemia, or AML.
The Foster City, Calif., biopharmaceutical company said HiFiBiO
will use its proprietary technology platforms to identify novel AML
targets and anti-AML specific antibodies for Kite's use in cell
therapies.
Financial details weren't disclosed, but Gilead said it will
make an upfront payment to HiFiBiO, and that the startup will be
eligible for additional payments based on Kite's opt-in on targets
discovered through the collaboration, along with development,
regulatory and commercial milestone.
HiFiBiO, which is developing drugs that harness the immune
system's ability to treat autoimmune disorders and cancer, raised
$67 million in a Series C funding round in August 2019.
-Brian Gormley contributed to this article
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 03, 2020 08:41 ET (12:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024